Leonard G. Gomella, MD

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.

Leonard G. Gomella, MD, discusses using novel biomarkers to inform whether a biopsy is needed in prostate cancer.

Leonard G. Gomella, MD, discusses the role of genetic testing in prostate cancer.

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of genetic testing in prostate cancer.

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the potential impact of targeted therapy approvals on the use of genetic testing in prostate cancer.

Leonard G. Gomella, MD, discusses recommendations for screening in prostate cancer.

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of androgen receptor (AR) inhibitors in prostate cancer.

Leonard G. Gomella, MD, professor, chair, Department of Urology, and director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the state of genetic testing in prostate cancer.

Leonard G. Gomella, MD, discusses the challenges of genetic testing in prostate cancer.

Leonard G. Gomella, MD, discusses the role of prostate-specific antigen screening in the early detection of prostate cancer.

Leonard G. Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the prevalence of genetic testing in prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the role of BRCA1/2 in patients with prostate cancer.

Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and director of the Kimmel Cancer Center Network, discusses the current perspectives on screening for prostate cancer.

Leonard Gomella, MD, urology specialist from Jefferson University, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.

The 12-month countdown to the adoption of ICD-10 has begun. ICD-10 represents the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (usually referred to as "ICD"), now overseen by the World Health Organization (WHO).

Leonard G. Gomella, MD, chair of Urology at Thomas Jefferson University Hospital and Director of Clinical Affairs at the Kimmel Cancer Center, discusses the debate surrounding PSA-based screening in prostate cancer in 2013.

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the clinical guidelines released by the American Urological Association at its 2013 Annual Meeting.

Leonard G. Gomella, MD, form the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the novel therapeutic radium-223, which is awaiting a decision from the FDA as a treatment for men with advanced prostate cancer.

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital, describes the identification of appropriate surrogate endpoints for the evaluation of new therapies for patients with metastatic castration-resistant prostate cancer.

Leonard G. Gomella, MD, discusses the benefits of the multidisciplinary center at Jefferson Kimmel Cancer Center.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.

Dr. Leonard Gomella, form the Jefferson Kimmel Cancer Center, on the Impact of the New USPSTF PSA Rating.

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on the Provenge IMPACT Trial Survival Benefit

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses PSA Velocity

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Examines the Understating of Provenge Benefits

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on Helping Patients Make Informed Medical Decisions

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the Challenges of PSA Screening

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T